Table 1. Novel adjuvant formulations for evaluation in candidate HIV-1 vaccine clinical trials.
| Adjuvant (Source*) | Vaccine | Study |
|---|---|---|
| MF59 (GSK): Squalene-in-water emulsions | ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 | Pivotal phase 2b/3 trial (HVTN** 702), prime boost regimen in South Africa |
| HIV-DNA and bivalent gp120 (all subtype C) | Phase 1/2a trial (HVTN 108), 2 adjuvant arms | |
| ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 | 2 adjuvant arm study (in planning) | |
| AS01B (GSK): Liposome-based QS-21 + monophosphoryl lipid A | HIV-DNA and bivalent gp120/AS01B (all subtype C) | Phase 1/2a trial (HVTN 108), 2 adjuvant arms |
| eOD GT8 60-mer nanoparticle | Germline targeting Env immunogen (in planning) | |
| BG505 SOSIP.664 trimer | Well-ordered native-like soluble Env trimer (in planning) | |
| ALVAC-HIV (vCP2438) and bivalent subtype C gp120/AS01B | 2 adjuvant arm study (HVTN 120) (in planning) | |
| GLA-SE (IDRI): glucopyranosyl lipid A in stable emulsion | polyvalent gp120 | Phase 1 trial (HVTN) (in planning) |
| CH505 gp120 | Phase 1 trial (HVTN), B cell lineage (in planning) | |
| GLA-LSQ (IDRI): liposome-based glucopyranosyl lipid A and QS-21 | BG505.665 SOSIP trimer | Phase 1 trial (HVTN) (in planning) |
| 3M-052 (3M): TLR 7/8 agonists | BG505.665 SOSIP trimer | Phase 1 trial (HVTN) (in planning) |
*
Source abbreviations: GSK, GlaxoSmithKline; IDRI, Infectious Disease Research Institute.
**
HVTN, HIV Vaccine Trials Network.